Norplant is a subdermal implant providing contracep tive protection over a five-year period. After worldwide trials, it has been available in the UK since September

1993-The author discusses the mode of action of this contraceptive method, its efficacy, advantages and disadvantages and desaibes the procedure for insertion of the implants.
The Norplant subdermal implant is a low-dose, progestogen-only method of contraception that is long-acting, highly effective and reversible. It consists of six matchstick-sized, flexible, Silastic capsules, which are usually implanted under the medial surface of the non-dominant upper arm. These release a sustained low dose of levonorgestrel into the system at the levels needed to achieve effective contraception. The dose grad ually decreases over a five-year period, after which time its contraceptive efficacy starts to diminish. Although relatively new to the UK (it has been available since September 1993), clinical trials have involved 55,000 women in 44 countries over a period of 20 years (1) . It is estimated that three million women have used or are using Norplant worldwide. Efficacy Among women who are of average weight, the pregnancy rate after one year of use is 0.4 per 100 users. Pregnancy rates increase over five years, with a cumulative pregnancy rate of 1.6 per cent (2) . In one study, a direct corre lation was found between pregnancy rates and women with a weight of over 70kg (1) . This, however, was among women using a Norplant with a higher elastomer density in its capsule than the type available in the UK, which is now used worldwide.
Norplant works to prevent pregnancy in three ways. It thickens the cervical mucus (3) thus inhibiting sperm migration; it prevents ovula tion in around 50 per cent of cycles; and it may alter the endometrium to prevent implantation and further inhibit sperm migration. Norplant has been confirmed as being one of the most effective methods of contraception currently available. Disadvantages The side-effects of Norplant are irregular menstrual bleeding and progestogenrelated symptoms, and are typical of all pro gestogen-only contraceptive methods.
The irregular menstrual bleeding is caused by the erratic shedding of hypotrophic endometri um and includes altered spacing of bleeding episodes, changes in the duration and volume of blood loss, and spotting. In some cases (between 5 and 7 per cent), menstruation can stop alto gether. Between 60 and 82 per cent of women will experience menstrual changes during the first year of use (1) , but this settles down in most women after the first year. It is important to emphasise to the user that bleeding episodes can be longer than usual but that the total volume of blood loss is usually less.
Other side-effects are similar to those found with other hormonal contraceptives and affect approximately 10 per cent of users. They include headaches, nausea, depression and mood changes, abdominal cramps, hair loss or gain, change in appetite, fluid retention, breast pain, weight changes (gain more common than loss), galactorrhoea (milky nipple discharge), acne and chloasma. Other progestogen-related side-effects include non-functional ovarian cysts and a theoretically higher risk of a pregnancy being ectopic, especially if the Norplant is left in situ for more than five years.
Financial and human costs
Other supposed disadvantages are that the woman is dependent on a clinician to initiate and discontinue use of the method, the device may be visible under the skin (although this has not been our experience), it provides no protection against sexually transmitted diseases and finally, financial cost. If Norplant is used for the full five years, its cost is comparable to a modern com bined pill. If, however, the woman decides to have the device removed earlier, the financial cost increases. This should be weighed against the financial and human costs in terms of unwant ed pregnancy among women who would other wise use a less effective method of contraception. Advantages The main advantages of Norplant are its effectiveness, its convenience and ease of use, its reversibility, the avoidance of oestrogenassociated side-effects and that it lasts five years.
Of 138 women requesting Norplant at our centre in Leeds, 89 cited convenience as an important advantage, 87 cited effectiveness and 65 cited the absence of oestrogen-associated sideeffects. Of 145 women who have had Norplant fitted, 68 had no children, 57 had one or two and 20 had three or more. The hugest number of users were in the 20-29 years age group (80 users), 41 users were aged 30 or over and 24 users were aged 20 or under.
It appears therefore that Norplant will not be restricted to a particular group of users and is appealing to a wide range of women. Because it is safe and reversible (it is undetectable in the blood 24 hours after removal), it is suitable as a first choice method. Currently, depo-medroxyprogesterone acetate (Depo-provera) is only licensed to be used in women when no other suitable method can lie found.
The efficacy of the method is not reduced if the user takes antibiotics (apart from hepatic enzyme inducers such as rifampicin) or has an episode of diarrhoea and vomiting. It does not interfere with sexual intercourse and requires no forward planning, apart from the fitting. Preparing the user It is important that the woman is seen to discuss Norplant, preferably at least a day before the insertion. This allows her to make an informed choice and increases the likelihood that she will continue using the device should she experience menstrual changes or other side-effects. The aims of the initial appointment are, as for any family planning consultation, to discuss the benefits and limitations of the method, to assess and discuss her suitability and to check for any contraindications.
It is essential to reassure the client that should she experience problems with using the method, or should she change her mind for whatever reason, it can be removed and she should not feel a 'failure'. It is not always possible to predict which clients are likely to have problems or change their mind and it would be highly unethical for any healthcare professional to refuse to remove Noqdant. Insertion On the day of insertion, any queries the women has are discussed. Insertion takes 10-15 minutes. The procedure is described to the woman and she lies flat, with her arm out stretched in a comfortable position. The inser tion site is first marked using a stencil mapping where the Norplants are to go. The skin is then cleaned with a mild antiseptic and sterile towels are placed around the site. The Norplant is then inserted and the pro cedure is repeated until all six implants have been inserted in a fan shape. This is to avoid nicking the previous implant, which would allow the hormone to escape. It is helpful if someone is available to divert the patient's attention during the insertion procedure in order to reduce anxiety.
A Steristrip is applied over the insertion site, followed by a dressing and bandage. The ban dage should be left on for two to three days, in order to reduce the risk of haematoma formation. The woman should be warned to expect a fairly large biruise.
In our centre the procedure is usually carried out in the morning. Clients are advised to eat breakfast before attending, which seems to reduce the possibility of fainting. The client should l)e observed for at least five minutes fol lowing the insertion procedure. After-care Possible complications of insertion include infection, localised allergic reaction, expulsion, haematoma formation and reactions to dressings, all of which are relatively rare. In Leeds we have also had a few complaints about pain and tingling over the insertion site for several weeks after insertion, but this has settled down on its own in all cases. The client is advised to return if she experiences any discharge, itching, pain or other signs of infection.
The client should be seen approximately seven to ten days following insertion for the wound to be checked. After that, she will be seen in three months for her blood pressure to be checked and to discuss any problems. If all is well, the client will subsequently only need to be seen annually and should lie given a card advising her how to get in touch should she experience any problems.
Tlie client should also be given a card remind ing her when the removal date is due and told to keep it safe. It is advised that all centres fit ting Norplant develop a recall system. At St James's Hospital, all insertion dates are placed on a computer database. It the Norplant is inserted on the first day of the woman' s menstrual cycle, no other contra ceptive precautions are necessary. At any other time, additional non-hormonal contraception should lie used for seven days. Pregnancy should always lie ailed out prior to insertion.
Norplant can be fitted immediately follow ing termination of pregancy; if more than five days later, additional contraception would be required for seven days. Following childbirth, Noqilant can lie inserted from day 21, with an additional methtxl used for the first seven days. Removal Noqilant needs to lie replaced after five years as efficacy staas to diminish after this time. The procedure for removal takes approximately 15-20 minutes. A small incision is made near to the insertion site and the capsules are either removed with small forceps or pushed out with the fingers, depending on the degree of fibrosis. A new set of Norplant can then be inserted in the opposite direction if required. Qire of the site is the same as for insertion.
The average continuation rate for Norplant is 3.5 years. Continuation at five years varies from 30 per cent (3) to 78 per cent (2) . One study of 2,470 users in the US showed a continuation rate of 81 per cent at one year (3). It is too early to see if this will differ for women in the IJK. Other developments Other sustained-release con traceptive methods under investigation include a removable levonorgestrel-releasing vaginal ring (changed every three months), a levonorgestrelreleasing intrauterine device (lasting five years), two further non-biodegradable subdermal implants lasting two and three years, and a biodegradable implant lasting one year (Capronor). It is hoped that all of these will be available within the next few years
